News and Events

The pharmaceutical world is constantly evolving so it is paramount to stay up-to-date. Keep abreast of all Quinta’s announcements, insights and activities, as well as wider industry news right here.

  • 18 September 2024

    Determination of total bound iron in human blood serum samples

    Ironing out the challenges: measuring total bound iron in blood serum in Ferric Carboxymaltose (FCM) Studies

  • 4 September 2024

    Meet us at the heart of Pharma at CPHI 2024

    As a part of Conscio Group, we are attending CPHI 2024 in Milan, Italy.

  • 18 March 2024

    News from our newly opened clinic in Ostrava

    Our new Clinic in Ostrava (CZ) is gaining momentum step by step; therefore, we have some interesting news for you from the center of the action.

  • 19 December 2023

    Happy new year 2024

    As we bid farewell to 2023, it's time to express our deepest gratitude for the collaboration.

  • 4 December 2023

    Our new clinical unit in Ostrava comes to life

    It's a great pleasure to announce that after two years of hard work, the brand-new clinical unit in Ostrava with 36-beds capacity has been opened.

  • 3 October 2023

    Meet us at the heart of Pharma, CPHI 2023

    Quinta-Analytica is attending CPHI 2023 in Barcelona

  • 18 July 2023

    Challenges of a large-scale study of breast cancer

    Our bioanalytical experts and a high-profile client team up for the development of a new therapy for breast cancer.

  • 29 June 2023

    EU funding for Quinta-Analytica laboratory in Brno (CZ) was succesfully completed.

    After two years, the project to finance new equipment for the Quinta-Analytica laboratory in Brno was successfully completed. The investment from European Regional Development Fund was used in this project.

  • 22 June 2023

    Quinta Analytica Partners with EvidentIQ to Enhance Efficiency of Phase 1 Studies

    EvidentIQ partners with Quinta-Analytica to enhance Phase 1 study efficiency

  • 15 June 2023

    Novavax & Conscio: Behind the Scenes of Vaccine Development

    Discover how the Conscio Group and renowned vaccine manufacturer Novavax collaborate behind the scenes to ensure quality and efficiency in vaccine production.

  • 8 June 2023

    Ekolab And Conscio Group Join Forces

    Ekolab joins the Conscio Group, enhancing our analytical capabilities and solidifying our position in pharmaceutical, nutrition, and technology solutions.

  • 8 June 2023

    Clinical Tips – Drug Interactions in Advanced Clinical Trial Design

    Drug interactions play a key role in the design of clinical trials. Learn how we investigate such interactions when conducting pharmacokinetic/bioequivalence studies and while offering end-to-end support throughout the process.

  • 6 April 2023

    Transdermal Patches, Films and Topicals – Putting the Skin in the Game

    Today we talk about novel drug delivery systems and in vitro testing techniques. Learn about our work with transdermal patches, orally dissolving films, topical products and Franz cell testing.

  • 23 March 2023

    Clinical Tips – Benefits of Sequential Designs in Bioequivalence Studies

    Discover the power of sequential designs for bioequivalence studies, a crucial step in generics development: Their practical implementation, statistical analysis, and the well-being of the volunteers.

  • 23 March 2023

    A Prescription Against EU Medicine Shortages – Outsourcing Stabilities

    We highlight the reasons behind current EU drug shortages and the key role CROs and outsourced stability testing play in diversifying drug production.

  • 27 January 2023

    Pharmaceutical Offshore Outsourcing in the USA: Opportunities & Misconceptions

    Dr. Jeffrey Kiel, founder and CEO of Kiel Laboratories, talks about offshore outsourcing in the USA and working with Quinta-Analytica.

  • 5 January 2023

    From Houston to Munich – Innovation & Compounding

    Pharma innovators often outsource demanding projects to specialist CROs. Gus Bassani of US-based PCCA and Markus Dachtler of Conscio's German subsidiary Gen-Plus, share lessons from their collaboration.

  • 7 December 2022

    Quinta’s Another Two Successful FDA Inspections

    We at Quinta-Analytica are proud to announce the successful completion of not 1 but 2 FDA inspections at our Prague and Brno sites. Thanks for your trust and support!

  • 24 November 2022

    The Secret Behind 25 Years of Excellence

    Quinta-Analytica's 25th Anniversary give us the chance to look back at our successful trajectory of proactiveness, technical expertise and improvement in the company of Dr Miroslav Ryska, mass spectrometry expert and founder of Quinta.

  • 24 November 2022

    Quinta-Analytica + Olga Havel Foundation – Helping to Help Others

    We are proud to announce that Quinta-Analytica has donated 100,000 CZK to the Olga Havel Foundation for the support of six families with members in need of neurorehabilitation.

  • 24 November 2022

    Nitrosamine Analogues: Stepping up to a new Challenge

    Have you heard about Nitrosamine Analogues? Did you know even if a tested API is free of nitrosamine analogues, its related drug product may still contain high amounts of these new impurities? Keep reading to learn more!

  • 24 November 2022

    New Stability Models for Faster & Better Shelf Life Estimations

    Are you a pharma company in need of stability testing but have just too many candidates to screen with conventional ICH assays? We at Quinta-Analytica can offer you accurate stability data 3 times faster than usual! Find out more below.